JOP. 2008 May 8;9(3):305-8.

Response to a third-line mitomycin C (MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline BRCA2 mutation.

Source

Arizona Cancer Center, University Medical Center, Tucson, AZ 85724, USA.

Abstract

CONTEXT:

Gemcitabine remains the mainstay of palliative chemotherapy for those patients with unresectable or metastatic pancreatic cancer. Objective radiological responses to gemcitabine are rare and reported median survival is only about six months. New therapeutic concepts and strategies are needed in order to improve those dismal statistics.

CASE REPORT:

We report here a case of a patient with metastatic pancreatic cancer responding to a third-line therapy with combination of mitomycin C and capecitabine. Interestingly, the patient had a strong family history of breast cancer and tested positive to germline BRCA2 mutation.

CONCLUSION:

We feel that this is of interest because of preclinical reports of increased sensitivity of pancreatic cells carrying BRCA2 mutations to DNA-intercalating agents such as mitomycin C. Further research and clinical trials are warranted to support this novel concept.

PMID:: 18469443; [PubMed - indexed for MEDLINE]

Free full text

LinkOut - more resources

Supplemental Content

Save items

Related citations in PubMed

Review Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature. [Anticancer Drugs. 2009]
Review Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature.
James E, Waldron-Lynch MG, Saif MW. Anticancer Drugs. 2009 Aug; 20(7):634-8.
Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy. [Cancer Biol Ther. 2011]
Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy.
Sonnenblick A, Kadouri L, Appelbaum L, Peretz T, Sagi M, Goldberg Y, Hubert A. Cancer Biol Ther. 2011 Aug 1; 12(3):165-8. Epub 2011 Aug 1.
Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer. [Am J Clin Oncol. 2009]
Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.
Lee S, Oh SY, Kim BG, Kwon HC, Kim SH, Rho MH, Kim YH, Rho MS, Jeong JS, Kim HJ. Am J Clin Oncol. 2009 Aug; 32(4):348-52.
A 67-year-old woman with BRCA 1 mutation associated with pancreatic adenocarcinoma. [J Gastrointest Cancer. 2011]
A 67-year-old woman with BRCA 1 mutation associated with pancreatic adenocarcinoma.
Lowery M, Shah MA, Smyth E, Epstein A, Segal A, Rosengarten O, Isacson R, Drukker L, Keinan A, Rachkiman M, et al. J Gastrointest Cancer. 2011 Sep; 42(3):160-4.
Review A carrier of both MEN1 and BRCA2 mutations: case report and review of the literature. [Cancer Genet Cytogenet. 2007]
Review A carrier of both MEN1 and BRCA2 mutations: case report and review of the literature.
Ghataorhe P, Kurian AW, Pickart A, Trapane P, Norton JA, Kingham K, Ford JM. Cancer Genet Cytogenet. 2007 Dec; 179(2):89-92.

See reviews... See all...

Cited by 2 PubMed Central articles

Drug therapy for hereditary cancers. [Hered Cancer Clin Pract. 2011]
Drug therapy for hereditary cancers.
Imyanitov EN, Moiseyenko VM. Hered Cancer Clin Pract. 2011 Aug 6; 9(1):5. Epub 2011 Aug 6.
Review Pancreatic cancer: pathobiology, treatment options, and drug delivery. [AAPS J. 2010]
Review Pancreatic cancer: pathobiology, treatment options, and drug delivery.
Li J, Wientjes MG, Au JL. AAPS J. 2010 Jun; 12(2):223-32. Epub 2010 Mar 3.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Response to a third-line mitomycin C (MMC)-based chemotherapy in a patient with ...
Response to a third-line mitomycin C (MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline BRCA2 mutation.
JOP. 2008 May 8 ;9(3):305-8.

PubMed
Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate a...
Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists.
Nature. 1991 Jan 31 ;349(6308):414-8.

PubMed
Linkage to treatment and supportive services among HIV-positive ex-offenders in ...
Linkage to treatment and supportive services among HIV-positive ex-offenders in Project Bridge.
J Health Care Poor Underserved. 2008 May ;19(2):522-31.

PubMed
Wastewater irrigation of salad crops: further evidence for the evaluation of the...
Wastewater irrigation of salad crops: further evidence for the evaluation of the WHO guidelines.
Water Sci Technol. 2008 ;57(8):1213-9.

PubMed
Elucidating the relationship between DISC1, NDEL1 and NDE1 and the risk for schi...
Elucidating the relationship between DISC1, NDEL1 and NDE1 and the risk for schizophrenia: evidence of epistasis and competitive binding.
Hum Mol Genet. 2008 Aug 15 ;17(16):2462-73. Epub 2008 May 10 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Response to a third-line mitomycin C (MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline BRCA2 mutation.

Source

Abstract

CONTEXT:

CASE REPORT:

CONCLUSION:

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

Cited by 2 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information